Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.98M 16.53M 15.3M 14.33M 26.85M 1.79B 27.05M 70.36M 880M 71.25M 69.72M 3.08B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.31M 35.98M 33.3M 31.19M 58.43M 3.9B 58.88M 153M 1.92B 155M 152M 6.71B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

IRRAS AB Stock OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news : IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	16.9M
STRYKER CORPORATION	+2.21%	+0.71%	-17.54%	+4.57%	118B
SMITH & NEPHEW PLC	-0.66%	-1.01%	+5.44%	-10.39%	12.72B
GLAUKOS CORPORATION	+2.57%	+5.17%	+27.69%	+92.97%	7.67B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.48%	-1.28%	-46.91%	-72.29%	4.07B
DOUBLE MEDICAL TECHNOLOGY INC.	+1.51%	+2.35%	+18.57%	+34.36%	2.56B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.94%	+4.16%	-14.60%	-16.91%	1.78B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.21%	-2.45%	+2.33%	-19.56%	1.59B
L&C BIO CO.,LTD	+5.36%	+0.12%	+184.99%	+154.14%	1.41B
Average	-0.35%	+1.04%	+20.00%	+20.86%	18.72B
Weighted average by Cap.	+1.91%	+0.76%	-11.30%	+7.14%

	2023	2024
Net sales	42.88M 4.48M 3.9M 3.61M 3.38M 6.33M 422M 6.38M 16.6M 208M 16.81M 16.45M 728M	57.98M 6.06M 5.27M 4.88M 4.57M 8.57M 571M 8.63M 22.45M 281M 22.73M 22.24M 984M
Net income	-209M -21.82M -19M -17.59M -16.47M -30.86M -2.06B -31.09M -80.87M -1.01B -81.89M -80.13M -3.54B	-95.98M -10.03M -8.73M -8.08M -7.57M -14.18M -946M -14.29M -37.16M -465M -37.63M -36.82M -1.63B
Net Debt	43.85M 4.58M 3.99M 3.69M 3.46M 6.48M 432M 6.53M 16.98M 212M 17.19M 16.82M 744M	214M 22.33M 19.45M 18M 16.86M 31.58M 2.11B 31.82M 82.77M 1.04B 83.81M 82.01M 3.63B